National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 1 of 1 Research Studies DisplayedLu CY, Zhang F, Lakoma MD
Asthma treatments and mental health visits after a Food and Drug Administration label change for leukotriene inhibitors.
This study investigated how a label change to include neuropsychiatric adverse events (e.g., depression and suicidality) affected the use of leukotriene inhibitors (LTIs) and other asthma controller medications, mental health visits, and suicide attempts. The label change was associated with abrupt reductions in LTI use among all age groups.
AHRQ-funded; HS019669.
Citation: Lu CY, Zhang F, Lakoma MD .
Asthma treatments and mental health visits after a Food and Drug Administration label change for leukotriene inhibitors.
Clin Ther 2015 Jun;37(6):1280-91. doi: 10.1016/j.clinthera.2015.03.027..
Keywords: Adverse Drug Events (ADE), Asthma, Children/Adolescents, Medication, Behavioral Health